A brief review on high on-aspirin residual platelet reactivity

Vascular Pharmacology

Volumn 67, Issue , 2015, Pages 6-9

  Pettersen, A A ^a,b   Arnesen, H ^a,c   Seljeflot, I ^a,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b Ringerike Sykehus   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

Aspirin; Coronary artery disease; Cyclooxygenase; Platelet reactivity; Thromboxane

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; PROSTACYCLIN; THROMBOXANE A2; THROMBOXANE B2; ANTITHROMBOCYTIC AGENT;

BLOOD CLOTTING PARAMETERS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MECHANISM; ENDOTHELIUM CELL; HIGH ON ASPIRIN RESIDUAL PLATELET REACTIVITY; HUMAN; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PLATELET REACTIVITY; PRIORITY JOURNAL; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE RICH PLASMA; THROMBOCYTOPOIESIS; VASODILATATION; ANIMAL; BLOOD; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; PROCEDURES; THROMBOCYTE; VASCULAR ENDOTHELIUM;

ANIMALS; ASPIRIN; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HUMANS; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS;

EID: 84929280769     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2015.03.018     Document Type: Review

References (63)

1. Krasopoulos G., Brister S.J., Beattie W.S., Buchanan M.R. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008, 336:195-198.
2. Snoep J.D., Hovens M.M., Eikenboom J.C., van der Bom J.G., Huisman M.V. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007, 167:1593-1599.
3. Zimmermann N., Hohlfeld T. Clinical implications of aspirin resistance. Thromb Haemost 2008, 100:379-390.
4. Baigent C., Blackwell L., Collins R., Emberson J., Godwin J., Peto R., et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009, 373:1849-1860.
5. Patrono C., Bachmann F., Baigent C., Bode C., De Caterina R., Charbonnier B., et al. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J 2004, 25:166-181.
6. Collaboration A.T. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324:71-86.
7. De Gaetano G., Cerletti C. Aspirin resistance: a revival of platelet aggregation tests?. J Thromb Haemost 2003, 1:2048-2050.
8. Gianetti J., Parri M.S., Sbrana S., Paoli F., Maffei S., Paradossi U., et al. Platelet activation predicts recurrent ischemic events after percutaneous coronary angioplasty: a 6months prospective study. Thromb Res 2006, 118:487-493.
9. Gum P.A., Kottke-Marchant K., Welsh P.A., White J., Topol E.J. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003, 41:961-965.
10. Marcucci R., Paniccia R., Antonucci E., Gori A.M., Fedi S., Giglioli C., et al. Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events. Am J Cardiol 2006, 98:1156-1159.
11. Patrono C., Andreotti F., Arnesen H., Badimon L., Baigent C., Collet J.P., et al. Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J 2011, 32:2922-2932.
12. Craven L.L. Experiences with aspirin (acetylsalicylic acid) in the nonspecific prophylaxis of coronary thrombosis. Miss Valley Med J 1953, 75:38-44.
13. Craven L.L. Prevention of coronary and cerebral thrombosis. Miss Valley Med J 1956, 78:213-215.
14. Gibson P.C. Aspirin in the treatment of vascular diseases. Lancet 1949, 2:1172-1174.
15. Smith W.L., DeWitt D.L., Shimokawa T., Kraemer S.A., Meade E.A. Molecular basis for the inhibition of prostanoid biosynthesis by nonsteroidal anti-inflammatory agents. Stroke 1990, 21:IV24-IV28.
16. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971, 231:232-235.
17. Cox D., Maree A.O., Dooley M., Conroy R., Byrne M.F., Fitzgerald D.J. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke 2006, 37:2153-2158.
18. Pedersen A.K., FitzGerald G.A. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med 1984, 311:1206-1211.
19. Patrono C., Ciabattoni G., Pinca E., Pugliese F., Castrucci G., De Salvo A., et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res 1980, 17:317-327.
20. Spenney J.G. Acetylsalicylic acid hydrolase of gastric mucosa. Am J Physiol 1978, 234:E606-E610.
21. Williams F.M., Mutch E.M., Nicholson E., Wynne H., Wright P., Lambert D., et al. Human liver and plasma aspirin esterase. J Pharm Pharmacol 1989, 41:407-409.
22. Hutt A.J., Caldwell J., Smith R.L. The metabolism of aspirin in man: a population study. Xenobiotica 1986, 16:239-249.
23. Perneby C., Wallen N.H., Rooney C., Fitzgerald D., Hjemdahl P. Dose- and time-dependent antiplatelet effects of aspirin. Thromb Haemost 2006, 95:652-658.
24. FitzGerald G.A. Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. Am J Cardiol 1991, 68:11B-15B.
25. Czervionke R.L., Smith J.B., Fry G.L., Hoak J.C., Haycraft D.L. Inhibition of prostacyclin by treatment of endothelium with aspirin. Correlation with platelet adherence. J Clin Invest 1979, 63:1089-1092.
26. Jaffe E.A., Weksler B.B. Recovery of endothelial cell prostacyclin production after inhibition by low doses of aspirin. J Clin Invest 1979, 63:532-535.
27. Doroszko A., Szahidewicz-Krupska E., Janus A., Jakubowski M., Turek A., Ilnicka P., et al. Endothelial dysfunction in young healthy men is associated with aspirin resistance. Vascul Pharmacol 2015, 2:001.
28. Grotemeyer K.H. Effects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in a subpopulation of treated patients. Thromb Res 1991, 63:587-593.
29. Grotemeyer K.H., Scharafinski H.W., Husstedt I.W. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 1993, 71:397-403.
30. Helgason C.M., Tortorice K.L., Winkler S.R., Penney D.W., Schuler J.J., McClelland T.J., et al. Aspirin response and failure in cerebral infarction. Stroke 1993, 24:345-350.
31. Helgason C.M., Bolin K.M., Hoff J.A., Winkler S.R., Mangat A., Tortorice K.L., et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994, 25:2331-2336.
32. Coller B.S. Platelet aggregation by ADP, collagen and ristocetin: a critical review of methodology and analysis 1979, CRC Press, Boca Raton, FL.
33. Chakroun T., Addad F., Abderazek F., Ben-Farhat M., Hamdi S., Gamra H., et al. Screening for aspirin resistance in stable coronary artery patients by three different tests. Thromb Res 2007, 121:413-418.
34. Grove E.L., Hvas A.M., Johnsen H.L., Hedegaard S.S., Pedersen S.B., Mortensen J., et al. A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. Thromb Haemost 2010, 103:1245-1253.
35. Lordkipanidze M., Pharand C., Schampaert E., Turgeon J., Palisaitis D.A., Diodati J.G. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007, 28:1702-1708.
36. Muir A.R., McMullin M.F., Patterson C., McKeown P.P. Assessment of aspirin resistance varies on a temporal basis in patients with ischaemic heart disease. Heart 2009, 95:1225-1229.
37. Reilly I.A., FitzGerald G.A. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 1987, 69:180-186.
38. Santilli F., Rocca B., De Cristofaro R., Lattanzio S., Pietrangelo L., Habib A., et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance". J Am Coll Cardiol 2009, 53:667-677.
39. Ciabattoni G., Pugliese F., Davi G., Pierucci A., Simonetti B.M., Patrono C. Fractional conversion of thromboxane B2 to urinary 11-dehydrothromboxane B2 in man. Biochim Biophys Acta 1989, 992:66-70.
40. Roberts L.J., Sweetman B.J., Oates J.A. Metabolism of thromboxane B2 in man. Identification of twenty urinary metabolites. J Biol Chem 1981, 256:8384-8393.
41. Lee P.Y., Chen W.H., Ng W., Cheng X., Kwok J.Y., Tse H.F., et al. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med 2005, 118:723-727.
42. von Pape K.W., Strupp G., Bonzel T., Bohner J. Effect of compliance and dosage adaptation of long term aspirin on platelet function with PFA-100 in patients after myocardial infarction. Thromb Haemost 2005, 94:889-891.
43. Grove E.L., Hvas A.M., Kristensen S.D. Immature platelets in patients with acute coronary syndromes. Thromb Haemost 2009, 101:151-156.
44. Guthikonda S., Lev E.I., Patel R., DeLao T., Bergeron A.L., Dong J.F., et al. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost 2007, 5:490-496.
45. Rocca B., Secchiero P., Ciabattoni G., Ranelletti F.O., Catani L., Guidotti L., et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci U S A 2002, 99:7634-7639.
46. Henry P., Vermillet A., Boval B., Guyetand C., Petroni T., Dillinger J.G., et al. 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease. Thromb Haemost 2011, 105:336-344.
47. Wurtz M., Hvas A.M., Jensen L.O., Kaltoft A.K., Tilsted H.H., Kristensen S.D., et al. 24-hour antiplatelet effect of aspirin in patients with previous definite stent thrombosis. Int J Cardiol 2014, 175:274-279.
48. Capone M.L., Sciulli M.G., Tacconelli S., Grana M., Ricciotti E., Renda G., et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol 2005, 45:1295-1301.
49. Catella-Lawson F., Reilly M.P., Kapoor S.C., Cucchiara A.J., DeMarco S., Tournier B., et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001, 345:1809-1817.
50. Fitzgerald D.J., Maree A. Aspirin and clopidogrel resistance. Hematol Am Soc Hematol Educ Prog 2007, 114-120.
51. Malinin A.I., Ong S., Makarov L.M., Petukhova E.Y., Serebruany V.L. Platelet inhibition beyond conventional antiplatelet agents: expanding role of angiotensin receptor blockers, statins and selective serotonin reuptake inhibitors. Int J Clin Pract 2006, 60:993-1002.
52. Hillarp A. Acetylsalicylic acid resistance-clinical diagnosis with unclear mechanism. Lakartidningen 2004, 101:3504-3506. [3508].
53. Hillarp A., Palmqvist B., Lethagen S., Villoutreix B.O., Mattiasson I. Mutations within the cyclooxygenase-1 gene in aspirin non-responders with recurrence of stroke. Thromb Res 2003, 112:275-283.
54. Schwartz K.A., Schwartz D.E., Ghosheh K., Reeves M.J., Barber K., DeFranco A. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol 2005, 95:973-975.
55. Meen O., Brosstad F., Khiabani H., Gjertsen E., Lauritsen M.E., Pedersen T.M., et al. No case of COX-1-related aspirin resistance found in 289 patients with symptoms of stable CHD remitted for coronary angiography. Scand J Clin Lab Invest 2008, 68:185-191.
56. Michelson A.D., Cattaneo M., Eikelboom J.W., Gurbel P., Kottke-Marchant K., Kunicki T.J., et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 2005, 3:1309-1311.
57. Frelinger A.L., Furman M.I., Linden M.D., Li Y., Fox M.L., Barnard M.R., et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation 2006, 113:2888-2896.
58. Hedegaard S.S., Hvas A.M., Grove E.L., Refsgaard J., Rocca B., Davi G., et al. Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration. Thromb Res 2009, 124:96-100.
59. Hovens M.M., Snoep J.D., Eikenboom J.C., van der Bom J.G., Mertens B.J., Huisman M.V. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am Heart J 2007, 153:175-181.
60. Tantry U.S., Bliden K.P., Gurbel P.A. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 2005, 46:1705-1709.
61. Pettersen A.A., Seljeflot I., Abdelnoor M., Arnesen H. High on-aspirin platelet reactivity and clinical outcome in patients with stable coronary artery disease: results from ASCET (Aspirin Nonresponsiveness and Clopidogrel Endpoint Trial). J Am Heart Assoc 2012, 1:e000703.
62. Reny J.L., De Moerloose P., Dauzat M., Fontana P. Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost 2008, 6:444-450.
63. Reny J.L., Berdague P., Poncet A., Barazer I., Nolli S., Fabbro-Peray P., et al. Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: results of the Antiplatelet Drug Resistances and Ischemic Events study. Circulation 2012, 125:3201-3210.